1. COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study.
- Author
-
Cohen, Alexander T., Maraveyas, Anthony, Beyer-Westendorf, Jan, Lee, Agnes Y. Y., Mantovani, Lorenzo G., and Bach, Miriam
- Subjects
THROMBOEMBOLISM prevention ,ENOXAPARIN ,RIVAROXABAN ,ANTICOAGULANTS ,FATIGUE (Physiology) ,HEMORRHAGE ,LONGITUDINAL method ,MEDICAL history taking ,HEALTH outcome assessment ,PATIENT satisfaction ,QUALITY of life ,QUESTIONNAIRES ,THROMBOEMBOLISM ,TUMORS ,VEINS ,VITAMIN K ,DISEASE relapse ,TREATMENT effectiveness ,DISEASE incidence ,FUNCTIONAL assessment ,CHEMICAL inhibitors ,DISEASE complications ,THERAPEUTICS - Abstract
Background: Around 20% of venous thromboembolism (VTE) cases occur in patients with cancer. Current guidelines recommend low molecular weight heparin (LMWH) as the preferred anticoagulant for VTE treatment. However, some guidelines state that vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) are acceptable alternatives for long-term therapy in some patients if LMWHs are not available. LMWHs and VKAs have a number of drawbacks that can increase the burden on patients. DOACs, such as rivaroxaban, can ameliorate some burdens and may offer an opportunity to increase patient satisfaction and health-related quality of life (HRQoL). The Cancer-associated thrOmboSIs – patient-reported outcoMes with rivarOxaban (COSIMO) study is designed to provide real-world information on treatment satisfaction in patients with active cancer who switch from LMWH or VKA to rivaroxaban for the treatment of acute VTE or to prevent recurrent VTE. Methods: COSIMO is a prospective, non-interventional, single-arm cohort study that aims to recruit 500 patients in Europe, Canada and Australia. Adults with active cancer who are switching to rivaroxaban having received LMWH/VKA for the treatment and secondary prevention of recurrent VTE for at least the previous 4 weeks are eligible. Patients will be followed for 6 months. The primary outcome is treatment satisfaction assessed as change in the Anti-Clot Treatment Scale (ACTS) Burdens score at week 4 after enrolment compared with baseline. Secondary outcomes include treatment preferences, measured using a discrete choice experiment, change in ACTS Burdens score at months 3 and 6, and change in HRQoL (assessed using the Functional Assessment of Chronic Illness Therapy – Fatigue questionnaire). COSIMO will collect data on patients’ medical history, patterns of anticoagulant use and incidence of bleeding and thromboembolic events. Study recruitment started in autumn 2016. Conclusions: COSIMO will provide information on outcomes associated with switching from LMWH or VKA therapy to rivaroxaban for the treatment or secondary prevention of cancer-associated thrombosis in a real-life setting. The key goal is to assess whether there is a change in patient-reported treatment satisfaction. In addition, COSIMO will facilitate the evaluation of the safety and effectiveness of rivaroxaban in preventing recurrent VTE in this patient population. Trial registration:
NCT02742623 . Registered 19 April 2016. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF